Brief: Ryvu Therapeutics Says Poland's Medicines Authority Allows For Phase I Trial Of SEL120
07/01/2021 16:21
Jan 7 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* POLAND'S MEDICINES AUTHORITY URPL GRANTS PERMISSION TO
COMPANY
FOR PHASE I TRIAL INVESTIGATING SEL120
Source text for Eikon: ID:nEMDnzbJa
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys